Lowest Price Guaranteed
Pages
190
Last Updated
June 2026
View Count
11145
1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Introduction
2.4.2.2. Types
2.4.2.2.1. Qualitative
2.4.2.2.2. Quantitative
2.4.2.3. Advantages
2.4.2.4. Techniques
2.4.2.4.1. Interviews
2.4.2.4.2. Surveys
2.4.2.4.3. Focus Groups
2.4.2.4.4. Observational Research
2.4.2.4.5. Social Media Interactions
2.4.2.5. Stakeholders
2.4.2.5.1. Company Executives (CXOs)
2.4.2.5.2. Board of Directors
2.4.2.5.3. Company Presidents and Vice Presidents
2.4.2.5.4. Key Opinion Leaders
2.4.2.5.5. Research and Development Heads
2.4.2.5.6. Technical Experts
2.4.2.5.7. Subject Matter Experts
2.4.2.5.8. Scientists
2.4.2.5.9. Doctors and Other Hospitals
2.4.2.6. Ethics and Integrity
2.4.2.6.1. Research Ethics
2.4.2.6.2. Data Integrity
2.4.3. Analytical Tools and Databases
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Forecast Methodology
3.1.1. Top-Down Approach
3.1.2. Bottom-Up Approach
3.1.3. Hybrid Approach
3.2. Market Assessment Framework
3.2.1. Total Addressable Market (TAM)
3.2.2. Serviceable Addressable Market (SAM)
3.2.3. Serviceable Obtainable Market (SOM)
3.2.4. Currently Acquired Market (CAM)
3.3. Forecasting Tools and Techniques
3.3.1. Qualitative Forecasting
3.3.2. Correlation
3.3.3. Regression
3.3.4. Time Series Analysis
3.3.5. Extrapolation
3.3.6. Convergence
3.3.7. Forecast Error Analysis
3.3.8. Data Visualization
3.3.9. Scenario Planning
3.3.10. Sensitivity Analysis
3.4. Key Considerations
3.4.1. Demographics
3.4.2. Market Access
3.4.3. Reimbursement Scenarios
3.4.4. Industry Consolidation
3.5. Robust Quality Control
3.6. Key Market Segmentations
3.7. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Overview of Major Currencies Affecting the Market
4.2.2.2. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Exchange Impact
4.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
4.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Overview of Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product (GDP)
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. R&D Innovation
4.2.11.7. Stock Market Performance
4.2.11.8. Supply Chain
4.2.11.9. Cross-Border Dynamics
5. EXECUTIVE SUMMARY
6. INTRODUCTION
6.1. Chapter Overview
6.2. Overview of RNAi Drug Delivery Market
6.2.1. Key Characteristics of RNAi Drug Delivery
6.2.2. Key Applications of the RNAi Drug Delivery
6.2.3. Challenges Associated with RNAi Drug Delivery
6.3. Future Perspective
7. COMPETITIVE LANDSCAPE
7.1. Chapter Overview
7.2. RNAi Drug Delivery Providers: Overall Market Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. RNAi Drug Delivery Market: Overall Market Landscape
7.2.4.1. Analysis by Technology Type
7.2.4.2. Analysis by Targeted Disease Type
7.2.4.3. Analysis by Delivery System Type
7.2.4.4. Analysis by Targeted Tissue Type
7.2.4.5. Analysis by Route of Administration
7.2.4.6. Analysis by End User
8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodologies
8.4. Company Competitiveness Analysis: RNAi Drug Delivery Providers
8.4.1. RNAi Drug Delivery Providers Based in North America (Peer Group 1)
8.4.2. RNAi Drug Delivery Providers Based in Europe (Peer Group 2)
8.4.3. RNAi Drug Delivery Providers Based in Asia-Pacific (Peer Group 3)
8.4.4. RNAi Drug Delivery Providers Based in Middle East and North Africa, and Latin America (Peer Group 4)
8.5. Key Findings
9. COMPANY PROFILES
9.1. Chapter Overview
9.2. Alnylam Pharmaceuticals
9.2.1. Company Overview
9.2.2. Financial Information
9.2.3. Service / Product Portfolio
9.2.4. Recent Developments and Future Outlook
* Similar details are presented for other below mentioned companies based on information in the public domain
9.3. Arrowhead Pharmaceuticals
9.4. Arcturus Therapeutics
9.5. Bayer
9.6. BioNTech
9.7. Dicerna Pharmaceuticals
9.8. Ionis Pharmaceuticals
9.9. Moderna Therapeutics
9.10. Novartis
9.11. Pfizer
9.12. Roche
9.13. Regeneron Pharmaceuticals
9.14. Sanofi
9.15. Takeda Pharmaceutical
9.16. Viridian Therapeutics
10. SWOT ANALYSIS
11. MARKET IMPACT ANALYSIS
11.1. Chapter Overview
11.2. Market Drivers
11.3. Market Restraints
11.4. Market Opportunities
11.5. Market Challenges
11.6. Conclusion
12. GLOBAL RNAi DRUG DELIVERY MARKET
12.1. Chapter Overview
12.2. Key Assumptions and Methodology
12.3. Trends Disruption Impacting Market
12.4. Global RNAi Drug Delivery Market, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
12.5. Multivariate Scenario Analysis
12.5.1. Conservative Scenario
12.5.2. Optimistic Scenario
12.6. Key Market Segmentations
13. MARKET OPPORTUNITIES BASED ON TYPE OF TECHNOLOGY
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Revenue Shift Analysis
13.4. Market Movement Analysis
13.5. Penetration-Growth (P-G) Matrix
13.6. RNAi Drug Delivery Market for SiRNA: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
13.7. RNAi Drug Delivery Market for miRNA: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
13.8. RNAi Drug Delivery Market for shRNA: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
13.9. RNAi Drug Delivery Market for Others: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
13.10. Data Triangulation and Validation
14. MARKET OPPORTUNITIES BASED ON TYPE OF TARGETED DISEASE
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Revenue Shift Analysis
14.4. Market Movement Analysis
14.5. Penetration-Growth (P-G) Matrix
14.6. RNAi Drug Delivery Market for Cancer: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.7. RNAi Drug Delivery Market for Viral Infection: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.8. RNAi Drug Delivery Market for Genetic Disorders: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.9. RNAi Drug Delivery Market for Metabolic Disorders: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.10. RNAi Drug Delivery Market for Other Diseases: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.11. Data Triangulation and Validation
15. MARKET OPPORTUNITIES BASED ON TYPE OF DELIVERY SYSTEM
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Revenue Shift Analysis
15.4. Market Movement Analysis
15.5. Penetration-Growth (P-G) Matrix
15.6. RNAi Drug Delivery Market for Nanoparticle Drug Delivery Technology: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
15.7. RNAi Drug Delivery Market for Pulmonary Drug Delivery Technology: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
15.8. RNAi Drug Delivery Market for Nucleic Acid Drug Delivery Technology: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
15.9. RNAi Drug Delivery Market for Aptamer Drug Delivery Technology: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
15.10. Data Triangulation and Validation
16. MARKET OPPORTUNITIES BASED ON TYPE OF TARGETED TISSUE
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Revenue Shift Analysis
16.4. Market Movement Analysis
16.5. Penetration-Growth (P-G) Matrix
16.6. RNAi Drug Delivery Market for Liver: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
16.7. RNAi Drug Delivery Market for Lungs: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
16.8. RNAi Drug Delivery Market for Brain: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
16.9. RNAi Drug Delivery Market for Heart: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
16.10. RNAi Drug Delivery Market for Others: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
16.11. Data Triangulation and Validation
17. MARKET OPPORTUNITIES BASED ON TYPE OF ROUTE OF ADMINISTRATION
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Revenue Shift Analysis
17.4. Market Movement Analysis
17.5. Penetration-Growth (P-G) Matrix
17.6. RNAi Drug Delivery Market for Intravenous: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
17.7. RNAi Drug Delivery Market for Intramuscular: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
17.8. RNAi Drug Delivery Market for Subcutaneous: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
17.9. RNAi Drug Delivery Market for Local Injection: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
17.10. RNAi Drug Delivery Market for Others: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
17.11. Data Triangulation and Validation
18. MARKET OPPORTUNITIES BASED ON TYPE OF END USER
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Revenue Shift Analysis
18.4. Market Movement Analysis
18.5. Penetration-Growth (P-G) Matrix
18.6. RNAi Drug Delivery Market for Pharmaceutical Companies: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18.7. RNAi Drug Delivery Market for Biotechnology Companies: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18.8. RNAi Drug Delivery Market for Contract Research Organizations (CROs): Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18.9. RNAi Drug Delivery Market for Academic and Research Institutions and Government and Regulatory Bodies: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18.10. RNAi Drug Delivery Market for Government and Regulatory Bodies: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18.11. Data Triangulation and Validation
19. MARKET OPPORTUNITIES FOR RNAi DRUG DELIVERY IN NORTH AMERICA
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Revenue Shift Analysis
19.4. Market Movement Analysis
19.5. Penetration-Growth (P-G) Matrix
19.6. RNAi Drug Delivery Market in North America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.6.1. RNAi Drug Delivery Market in the US: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.6.2. RNAi Drug Delivery Market in Canada: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.6.3. RNAi Drug Delivery Market in Mexico: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.7. Data Triangulation and Validation
20. MARKET OPPORTUNITIES FOR RNAi DRUG DELIVERY IN EUROPE
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Revenue Shift Analysis
20.4. Market Movement Analysis
20.5. Penetration-Growth (P-G) Matrix
20.6. RNAi Drug Delivery Market in Europe: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.6.1. RNAi Drug Delivery Market in Germany: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.6.2. RNAi Drug Delivery Market in France: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.6.3. RNAi Drug Delivery Market in Italy: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.6.4. RNAi Drug Delivery Market in Spain: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.6.5. RNAi Drug Delivery Market in the UK: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.6.6. RNAi Drug Delivery Market in Rest of Europe: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.7. Data Triangulation and Validation
21. MARKET OPPORTUNITIES FOR RNAi DRUG DELIVERY IN ASIA-PACIFIC
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Revenue Shift Analysis
21.4. Market Movement Analysis
21.5. Penetration-Growth (P-G) Matrix
21.6. RNAi Drug Delivery Market in Asia-Pacific: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.6.1. RNAi Drug Delivery Market in China: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.6.2. RNAi Drug Delivery Market in India: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.6.3. RNAi Drug Delivery Market in Japan: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.6.4. RNAi Drug Delivery Market in South Korea: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.6.5. RNAi Drug Delivery Market in Rest of the Asia-Pacific: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.7. Data Triangulation and Validation
22. MARKET OPPORTUNITIES FOR RNAi DRUG DELIVERY IN MIDDLE EAST AND NORTH AFRICA (MENA)
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Revenue Shift Analysis
22.4. Market Movement Analysis
22.5. Penetration-Growth (P-G) Matrix
22.6. RNAi Drug Delivery Market in Middle East and North Africa (MENA): Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.6.1. RNAi Drug Delivery Market in Egypt: Historical Trends (Since 2020) and Forecasted Estimates (Till 205)
22.6.2. RNAi Drug Delivery Market in Saudi Arabia: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.6.3. RNAi Drug Delivery Market in United Arab Emirates (UAE): Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.7. Data Triangulation and Validation
23. MARKET OPPORTUNITIES FOR RNAi DRUG DELIVERY IN LATIN AMERICA
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Revenue Shift Analysis
23.4. Market Movement Analysis
23.5. Penetration-Growth (P-G) Matrix
23.6. RNAi Drug Delivery Market in Latin America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.6.1. RNAi Drug Delivery Market in Argentina: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.6.2. RNAi Drug Delivery Market in Brazil: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.7. Data Triangulation and Validation
24. APPENDIX 1: TABULATED DATA
25. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
26. CUSTOMIZATION OPPORTUNITIES
27. ROOTS SUBSCRIPTION SERVICES
28. AUTHOR DETAIL